Investors in pharma and auto stocks are anxious ahead of the April 2 deadline for US tariffs. Despite a 6% fall over three ...

India's pharmaceutical industry is urging its government to negotiate with Washington from a “position of power” on tariffs ...

India emphasized that the weighted tariff it levies has come down from 17% in 2023 to 10.66%, following changes in duty ...

The session highlighted existing policy support mechanisms and upcoming opportunities under the PRIP scheme aimed at ...

The move follows the approval from the National Company Law Tribunal (NCLT), New Delhi Bench. With this consolidation, the ...

U.S. President Trump imposes 25% tariff on auto imports, spotlight on pharma imports, Indian industry at risk.

India is deeply concerned about the effects of Trump’s global tariff strategy, set to take effect on April 2, which could ...

Hetero Group founder, B Parthasaradhi Reddy, warns of potential US reciprocal tariffs on Indian pharmaceuticals, which could ...

Pharma stocks are under significant selling pressure. Here is a detailed analysis on the top worries for the sector.

The industry needs to embrace innovation with technology towards novel drug development to remain relevant in the marketplace.

The Nippon India Pharma Fund - Growth has an AUM of 7637.04 crores & has delivered CAGR of 29.65% in the last 5 years. The fund has an exit load of 1.00% and an expense ratio of 1.82%. The minimum ...